This study systematically analyzes the current status of clinical research on PARP inhibitors in the treatment of prostate cancer, with several key findings: First, the research and development process shows clear phase‐specific characteristics, with Phase II clinical trials accounting for the highest proportion (42.2%), and the number of such trials (n = 46) far surpassing other phases. This evidence concerns the gene PARP1 and prostate carcinoma.